stable angina (37%), unstable angina (54%), and postinfarction angina after recent (<1 month) myocardial infarction (8%). Patients with acute myocardial infarction and target vessels <2 mm in diameter were excluded. The mean age of the bypass graft was 8.3±3.0 years, and 17% were diffusely diseased and degenerated. Complex lesion morphology included total occlusion (6%), eccentricity (64%), ulceration (18%), and thrombus (28%). The TEC atherectomy cutter was successfully advanced through 144 lesions (91%), but technical failures occurred in 14 lesions (9%), and these were subsequently managed by successful balloon angioplasty. Quantitative angiography revealed an increase in lumen diameter from 0.9±0.5 mm, to 1.5±0.7 mm after TEC atherectomy, to 2.3±0.8 mm after percutaneous transluminal coronary angioplasty (PTCA) (P<.001), which corresponded to decreases in diameter stenosis from 75 ± 14%, to 58±20% after TEC atherectomy, to 36±22% after PTCA (P<.001). Device success was achieved in 39.2% (post-TEC atherectomy decrease in diameter stenosis .20%), and procedural success was achieved in 84% (final diameter stenosis <50% in the absence of a major complication). Angiographic complications were evident in 33 lesions (20.7%) immediately after TEC atherectomy and in 8 lesions (5%) after PTCA, including distal embolization (11.9%), no-reflow (8.8%), and abrupt closure (5.0%), but no perforations. Adjunctive PTCA (and other medical therapy) successfully managed 61% of rogressive improvements in balloon angioplasty equipment and technique have permitted the application of percutaneous transluminal coronary angioplasty (PTCA) to patients with increasingly complex coronary artery disease. Despite these improvements, there continues to be enormous interest in the development of alternative interventional devices angiographic complications. Serious clinical complications included in-hospital death in 3 patients (2.0%), emergency bypass surgery in 1 patient who died (0.7%), Q wave myocardial infarction in 3 patients (2.0%), non-Q wave myocardial infarction in 4 patients (2.7%), vascular injury requiring surgical repair and/or blood transfusion in 9 patients (6.1%), and hemorrhagic cerebral infarction in 4 patients (2.7%). Using a composite clinical end point defined as in-hospital death, emergency bypass surgery, or myocardial infarction, the strongest independent correlate (P<.001) of a severe clinical complication was the development of one or more serious angiographic complications (no-reflow, distal embolization, or abrupt closure) immediately after TEC atherectomy. Complete clinical follow-up was available in 118 (92%) of 128 eligible patients at an interval of 6.0±2.5 months after discharge. Late cardiac outcome included recurrent angina treated with medical therapy (18%), repeat percutaneous intervention on the original target lesion (26%), repeat coronary artery bypass surgery (5%), Q wave myocardial infarction (4%), and late cardiac death (7%). Angiographic Between December 1988 and June 1992, TEC atherectomy was performed on 158 saphenous vein graft lesions in 146 consecutive patients with a mean age of 65±8 years (78% men). Anginal symptoms were classified as 0 or I (4%), II (4%), III (47%), or IV (45%) according to the Canadian Cardiovascular Society classification. Clinical indications for atherectomy included stable angina (37%), unstable angina (54%), and postinfarction angina after recent (<1 month) myocardial infarction (8%). Prior PTCA or other percutaneous intervention had been performed in 22% of lesions. Patients with acute myocardial infarction and target vessels <2 mm in diameter were excluded from this study.
Description of Atherectomy Device
The TEC atherectomy device (Interventional Technologies, Inc, San Diego, Calif) consists of several components: a cutting catheter with a cone-shaped cutting head (5.SF, 6 .0F, 6.5F, 7.0F, and 7.5F sizes) with two stainless steel cutting blades attached to the distal end of a hollow torque tube; a hand-held motor-drive unit that attaches to the proximal end of the cutting catheter; a battery pack that attaches to and serves as the power source for the motor-drive unit; and a vacuum bottle that attaches to the motor-drive unit for collection of aspirated blood and tissue. A trigger on the bottom of the motor-drive unit activates cutting-blade rotation (750 rpm), and a sliding lever on top of the handle permits advancement or retraction of the cutter. A specially designed rotating hemostatic valve with a sidearm adapter connects the guiding catheter to the manifold for contrast injections and also permits infusion of warmed (37°C), pressurized (300 mm Hg), heparinized lactated Ringer's solution, which creates a slurry of aspirated blood and tissue. The TEC atherectomy guide wire (Interventional Technologies, Inc) consists of a 300-cm-long 0.014-in stainless steel wire shaft, a 2-cm floppy tip, and a 0.021-in ball at the end of the wire to prevent wire entrapment in the cutter.
Device selection was largely empirical, but in general the largest device was 1.0 to 1.5 mm smaller than the reference diameter of the target vessel. For vessels >3 mm in diameter with large amounts of thrombus, large cutters (7F or 7.5F) were used if possible because of better ability to aspirate thrombus. In diffusely diseased vessels or subtotal stenoses, a smaller cutter (5.5F) was generally used first, followed by a larger cutter or PTCA to achieve a final residual diameter stenosis <50%.
Atherectomy Procedure
All atherectomy procedures were performed according to a protocol approved by the Human Investigations Committee of William Beaumont Hospital. A special 1OF tungsten-braided soft-tip guiding catheter (Interventional Technologies, Inc) was recommended for all TEC atherectomy procedures, but a 9F guiding catheter (inner diameter >0.089 in) can be used with devices s6.0F. After the vessel ostium was engaged, the target lesion was crossed with the TEC atherectomy guide wire, and the floppy tip was positioned in the distal vessel so that the stiff portion of the wire was across the lesion. If difficulty in crossing the lesion was anticipated, a conventional 0.014-in angioplasty guide wire was used first, which was then exchanged for the TEC atherectomy guide wire by use of a 2.5F infusion catheter (Cordis, Inc, Miami, Fla). Once the wire was in position, the TEC atherectomy catheter was advanced up to the lesion, and lactated Ringer's solution was infused under pressure. By gripping the handle on the motor-drive unit, the operator depressed the trigger to activate cutter rotation and aspiration, and the lever was slowly advanced and retracted to traverse the entire lesion. In general, several (two to five) passes were made slowly (10 to 30 seconds per pass) through the lesion, until there was no further resistance to cutter advancement. Repeat angiography was performed after the cutter was retracted to assess the need for a larger device or for balloon angioplasty.
Medications
All patients were pretreated with aspirin at least 24 hours before the procedure. After the insertion of the arterial sheath, heparin 10 The TEC atherectomy cutter was successfully advanced through 144 lesions (91%). However, technical failures of TEC atherectomy occurred in 14 lesions (9%) and were due to failure to engage the vessel ostium with the guiding catheter in 1 lesion (0.6%), failure to cross with the TEC atherectomy device in 6 lesions (3.8%), and failure to treat the entire lesion in 7 lesions (4.4%). All technical failures were subsequently managed by successful balloon angioplasty.
Quantitative angiographic analysis revealed a reference diameter of 3.8+±0.9 mm and a lesion length of 9.1 +±7.1 mm. Minimal lumen diameter increased from 0.9±0.5 to 1.5±0.7 mm after TEC atherectomy and to 2.3±0.8 mm (P<.001) after final treatment (Fig 1A) . These absolute diameters corresponded to decreases in diameter stenoses from 75±14%, to 58±20% after TEC atherectomy and to 36±22% (P<.001) after final treatment (Fig 1B) . The (Fig 2) . Angiographic evidence for dissection was detected in 54 lesions (34.5%) after TEC atherectomy, including mild or moderate dissection (grade 1 or 2) in 28 lesions (18%), severe dissection with high-grade residual stenosis (grade 3) in 18 lesions (11.4%), and severe dissection with total occlusion of the vessel in 8 lesions (5.1%). After final angiography, however, angiographic dissection was detected in 26 lesions (16.4%), including mild or moderate dissection in 24 lesions (15.2%) and severe dissection with highgrade residual stenosis or total occlusion in 1 lesion each (1.2%). New filling defects consistent with thrombus and/or dissection were identified by angiography in 22 lesions (13.9%), all after TEC atherectomy. These filling defects persisted in 5 lesions (3.2%) despite overlapping balloon inflations, intracoronary thrombolytic therapy, and intravenous dextran.
Angiographic Complications
Significant angiographic complications were evident in 33 lesions (20.7%) immediately after TEC atherectomy, and additional angiographic complications were directly attributed to PTCA in 8 lesions (5%) ( Table 3) . Distal embolization (of atheromatous debris in 15 lesions and air embolism in 4 lesions) occurred in 19 lesions (11.9%): immediately after TEC atherectomy in 18 lesions (11.3%) (Fig 3) and after adjunctive PTCA in 1 lesion (0.6%). Despite further balloon inflations, intracoronary nitroglycerin, and thrombolytic agents, angiographic evidence for distal embolization persisted in 5 lesions (3.2%) and was associated with myocardial infarction in 3 patients. No-reflow was observed in 14 lesions (8.8%): immediately after TEC atherectomy in 7 lesions (4.4%) and after adjunctive PTCA in 7 lesions (4.4%) (Figs 3 and 4) . Normal antegrade flow could not be reestablished in 10 lesions (6.3%) despite further balloon inflations, large doses of intracoronary nitroglycerin (0.2 to 1.2 mg), thrombolytic therapy, intravenous low-molecular-weight dextran, and intracoronary verapamil in several cases. Severe dissection leading to abrupt closure occurred in 8 lesions (5.0%), all imme- (Fig 2) and therefore is unlike other atherectomy devices such as directional atherectomy (which relies on tissue cutting, storage, and retrieval) or high-speed mechanical rotational atherectomy with the Rotablator (which relies on tissue pulverization and abrasion). Unlike the discrete tissue fragnents that are usually retrieved by directional atherectomy, TEC atherectomy results in a slurry of blood and debris that does not lend itself easily to tissue analysis to confirm removal of either atheroma or thrombus. Angiographically, it was frequently difficult to distinguish tissue removal from "Dotter" effect, and in one study, no tissue (except red blood cells) was identified in 93% of TEC atherectomy specimens analyzed by light microscopy. 7 However, although another preliminary study using coronary angioscopy does not suggest a major role of tissue removal, TEC atherectomy does appear to be an effective device for aspiration of recent thrombus.8 In light of the ability of TEC atherectomy to aspirate thrombus, stenosis in the distal third of the vein graft (arrowhead) with a large amount of intraluminal thrombus (arrows). Middle, After the lesion was crossed with a guide wire, a 7.5F TEC atherectomy cutter was advanced up to the lesion, and multiple passes were performed. Right, After TEC atherectomy, there was improvement in luminal diameter, but significant thrombus remained (arrows), and there was focal cutoff of the apical portion of the LAD consistent with distal embolization (not shown). Bottom, Results of adjunctive percutaneous transluminal coronary angioplasty in the vein graft depicted in top panels. Top left, The residual lesion was dilated with a 40-mm-long balloon. Top right, After balloon angioplasty, there was TIMI 1 flow to the distal vessel consistent with no-reflow. Bottom left, After infusion of urokinase through the inflated balloon into the distal LAD, there was restoration of normal antegrade flow with minimal residual stenosis (arrowhead). Bottom right, After overnight infusion of heparin, the vein graft and distal vessel were widely patent. At follow-up angiography, the vein graft was totally occluded (not shown), but there was no evidence for myocardial infarction. the observation of new or persistent filling defects in 13.9% of lesions was confusing. However, further angioscopic observations suggest that TEC atherectomy frequently leads to intimal dissection and may "unroof' superficial atheroma and expose underlying organized thrombus.8 These angioscopic observations may explain the appearance of new filling defects and the potential for distal embolization immediately after TEC atherectomy or adjunctive angioplasty (or other devices such as directional atherectomy). Top left, Baseline angiography revealed total occlusion of the proximal portion of the graft (arrowhead). The occlusion was crossed with a guide wire, and the patient underwent an overnight infusion of urokinase (100 000 U/h) through an infusion wire (arrows). Top middle, After urokinase infusion, the graft remained occluded (black arrowhead), but distal injection through the infusion wire revealed a severe stenosis in the midbody of the vein graft with distal thrombus (white arrowheads). Top right, Transluminal extraction coronary (TEC) atherectomy was performed with a 7.5F cutter. Bottom left, After TEC atherectomy, there was improvement in the stenosis (black arrowhead) but poor distal runoff consistent with noreflow (white arrowheads). Bottom middle, Multiple overlapping balloon inflations were performed throughout the entire graft, and additional urokinase was administered.
Bottom right, After adjunctive percutaneous transluminal coronary angioplasty and urokinase, the bypass graft was patent with normal antegrade flow, but the distal vessel remained hazy. Several months later, follow-up angiography (not shown) revealed total occlusion of the graft.
Angiographic Results of TEC Atherectomy
Although the TEC atherectomy catheter successfully crossed 91% of lesions, the extent of lumen enlargement was disappointing. After TEC atherectomy, the average residual lumen diameter was 1.5±0.7 mm, which was (Fig 4) . Furthermore, PTCA resulted in improvement in lumen contour (Fig 2) and reduction in the incidence of severe dissection. Finally, angiographic success increased from 39% after TEC atherectomy alone to 84% after adjunctive PTCA (Fig  1B) , which compares favorably with recent reports of balloon angioplasty of saphenous vein grafts. [12] [13] [14] [15] [16] [17] [18] Safety of TEC Atherectomy in Vein Grafts
The complexity of lesions in this study is reflected in the baseline lesion characteristics, which include old (8.3 years) and degenerated grafts (17%) (Fig 2) , aortoostial location (21%), intraluminal filling defects consistent with thrombus (28%) (Figs 3 and 4) , and abnormal contour with marked irregularity and ulceration (18%). In reviewing the available literature, it is difficult to find any reports of lesions with similar characteristics; therefore, the complications must be considered in light of the complexity of the target lesions. Furthermore, many of these patients were referred by other interventional cardiologists who refused to consider PTCA, directional atherectomy, or stenting for these stenoses.
Nevertheless, despite these considerations, the overall incidence of complications was high ( Using the conventional dichotomous definition of restenosis, the 6-month angiographic restenosis rate after TEC atherectomy was 69% (Fig 5) , which is considerably higher than the 22% to 55% restenosis rates reported for balloon angioplasty37,38 and the 21% to 47% restenosis rates for stenting. [19] [20] [21] [22] [23] Although this restenosis rate is considerably higher than the 31% to 47% restenosis rates reported in some studies of directional atherectomy and excimer laser angioplasty in vein grafts,23'24 it is similar to the 60% to 63% restenosis rates reported in other studies.25-2 Randomized trials now in progress may provide additional information about the relative value of balloon angioplasty, directional atherectomy, and stenting. Although the perioperative mortality rates for repeat coronary artery bypass surgery are twofold to fourfold higher than for initial elective operations, 5-and 10-year survival rates are 84% to 94% and 75%, respectively.29-36 However, only 50% of patients are free of angina, and 5-year eventfree survival (in terms of death, myocardial infarction, angioplasty, or third operation) is only 64%. 30, 33 A disconcerting finding was the observation that 30% of lesions were totally occluded at the time of angiographic follow-up (Fig 5) , although none of these were associated with acute myocardial infarction. Although the need for target vessel revascularization and the general clinical status have been proposed as a superior method for assessing clinically significant restenotic lesions,39 target vessel revascularization was not required in one third of these total occlusions, and more than half of these patients were minimally symptomatic. The lack of need for late revascularization and the absence of symptoms in this subgroup may suggest that these lesions did not require initial revascularization by TEC atherectomy, that the occlusions were well collateralized, or that the concept of target vessel revascularization may be limited in the setting of postbypass multivessel disease. Recommendations for the Use of TEC Atherectomy This is a retrospective observational study; therefore, definitive recommendations about the use of TEC atherectomy cannot be made with certainty. However, although the theoretical benefits of the TEC atherectional atherectomy and TEC atherectomy in old vein tomy catheter suggest that this device could be the by guest on November 13, 2017 http://circ.ahajournals.org/ Downloaded from treatment of choice for degenerated vein grafts, the frequent development of angiographic complications and the high incidence of restenosis raise a reasonable question as to whether any percutaneous technique should be applied to such lesions. Furthermore, the frequent need for adjunctive angioplasty (to enlarge lumen dimensions or to manage complications) will certainly raise procedural costs, and the combination of TEC atherectomy plus balloon angioplasty has not been shown to be superior to angioplasty alone. Until further randomized studies in vein grafts are available, TEC atherectomy might be considered for debulking large but focal thrombi, followed by either balloon angioplasty, directional atherectomy, or stenting, to achieve maximal lumen enlargement and provide the best opportunity for long-term benefit. However, the application of TEC atherectomy to diffusely diseased and severely degenerated vein grafts should be used cautiously and only after repeat bypass surgery has been strongly considered.
Limitations of the Study
This is a retrospective nonrandomized observational study, and as such, was not designed to identify the best treatment for patients with vein graft stenoses. Also, these data are based on the first generation TEC atherectomy cutters, and it is possible that future design modifications and increased operator experience may improve the immediate and long-term results and safety of the procedure.
Conclusions
In patients with stenoses in saphenous vein bypass grafts, TEC atherectomy is limited by the small size of the device and suboptimal angiographic results, often requiring adjunctive balloon angioplasty. Although the incidence of serious clinical complications is similar to that of other percutaneous interventions in vein grafts, there is a high incidence of restenosis and late vessel occlusion. In patients with old, diffusely degenerated vein grafts, TEC atherectomy may be considered if repeat coronary bypass surgery is not a reasonable therapeutic alternative. Prospective randomized studies are needed to determine the best revascularization strategy for these patients.
